Quoin Pharmaceuticals Receives FDA Rare Pediatric Disease Designation For QRX003

Filing content

The company received FDA Rare Pediatric Disease Designation for QRX003 for the treatment of Peeling Skin Syndrome and plans to initiate a Phase 2 study by the end of 2026.